246 related articles for article (PubMed ID: 9779717)
1. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
Kollmannsberger C; Beyer J; Droz JP; Harstrick A; Hartmann JT; Biron P; Fléchon A; Schöffski P; Kuczyk M; Schmoll HJ; Kanz L; Bokemeyer C
J Clin Oncol; 1998 Oct; 16(10):3386-91. PubMed ID: 9779717
[TBL] [Abstract][Full Text] [Related]
2. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
Wierecky J; Kollmannsberger C; Boehlke I; Kuczyk M; Schleicher J; Schleucher N; Metzner B; Kanz L; Hartmann JT; Bokemeyer C
J Cancer Res Clin Oncol; 2005 Apr; 131(4):255-60. PubMed ID: 15627215
[TBL] [Abstract][Full Text] [Related]
3. Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins.
Smith MA; Rubinstein L; Cazenave L; Ungerleider RS; Maurer HM; Heyn R; Khan FM; Gehan E
J Natl Cancer Inst; 1993 Apr; 85(7):554-8. PubMed ID: 8455202
[TBL] [Abstract][Full Text] [Related]
4. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
5. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children.
Schneider DT; Hilgenfeld E; Schwabe D; Behnisch W; Zoubek A; Wessalowski R; Göbel U
J Clin Oncol; 1999 Oct; 17(10):3226-33. PubMed ID: 10506623
[TBL] [Abstract][Full Text] [Related]
6. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks.
Smith MA; Rubinstein L; Ungerleider RS
Med Pediatr Oncol; 1994; 23(2):86-98. PubMed ID: 8202047
[TBL] [Abstract][Full Text] [Related]
7. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.
Smith MA; Rubinstein L; Anderson JR; Arthur D; Catalano PJ; Freidlin B; Heyn R; Khayat A; Krailo M; Land VJ; Miser J; Shuster J; Vena D
J Clin Oncol; 1999 Feb; 17(2):569-77. PubMed ID: 10080601
[TBL] [Abstract][Full Text] [Related]
8. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols.
Nichols CR; Breeden ES; Loehrer PJ; Williams SD; Einhorn LH
J Natl Cancer Inst; 1993 Jan; 85(1):36-40. PubMed ID: 7677934
[TBL] [Abstract][Full Text] [Related]
9. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.
Kollmannsberger C; Hartmann JT; Kanz L; Bokemeyer C
J Cancer Res Clin Oncol; 1998; 124(3-4):207-14. PubMed ID: 9619748
[TBL] [Abstract][Full Text] [Related]
10. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
[TBL] [Abstract][Full Text] [Related]
11. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report.
Heyn R; Khan F; Ensign LG; Donaldson SS; Ruymann F; Smith MA; Vietti T; Maurer HM
Med Pediatr Oncol; 1994; 23(2):99-106. PubMed ID: 8202048
[TBL] [Abstract][Full Text] [Related]
13. Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide.
Houck W; Abonour R; Vance G; Einhorn LH
J Clin Oncol; 2004 Jun; 22(11):2155-8. PubMed ID: 15169802
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.
Beyer J; Kingreen D; Krause M; Schleicher J; Schwaner I; Schwella N; Huhn D; Siegert W
Cancer; 1997 Jan; 79(1):161-8. PubMed ID: 8988741
[TBL] [Abstract][Full Text] [Related]
15. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W
Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
[TBL] [Abstract][Full Text] [Related]
16. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
[TBL] [Abstract][Full Text] [Related]
17. Treatment of testicular cancer and the development of secondary malignancies.
Bokemeyer C; Schmoll HJ
J Clin Oncol; 1995 Jan; 13(1):283-92. PubMed ID: 7799032
[TBL] [Abstract][Full Text] [Related]
18. Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients.
Inoue Y; Nakamura T; Nakanishi H; Oishi M; Hongo F; Okihara K; Mizutani S; Kuroda J; Ukimura O
Int J Urol; 2018 Jul; 25(7):678-683. PubMed ID: 29752743
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
